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Objective: The use of rinse solutions before reperfusing liver allografts has been 
shown to reduce cell death in rats. Carolina rinse solution (an extracellular 
solution that contains antioxidants, vasodilators, and other substrates that help 
prevent ischemia-reperfusion njury) has also been shown to improve liver 
function clinically in liver transplant recipients. This pilot study evaluates the 
value of a second pulmonary artery flush before reperfusion of a lung graft. 
Methods: Six groups of Sprague-Dawley rats (n = 6 each) were subjected to the 
following:. Group 1 lungs were preserved with modified Euro-Collins solution 
followed by 24 hours of cold ischemia. Group 2 lungs were treated the same as 
group I but reperfused with blood. Group 3 lungs were preserved inCarolina rinse 
solution followed by 24 hours of cold ischemia. Group 4 lungs were treated the 
same as group 3 lungs and then reperfused with blood. Lungs in groups 5 and 6 
were preserved with Euro-Collins solution, stored cold for 24 hours, and then 
rinsed with Euro-Collins or Carolina rinse solution, respectively, before reperfu- 
sion with blood. Lungs were subsequently stained with tr31aan blue solution for 5 
minutes. Lung blocks were fixed and embedded in water-soluble methacrylate. 
Trypan blue-stained nuclei in nonviable ndothelial cells and alveolar pneumo- 
cytes were counted in 10 different fields. Results: Groups 1 and 3, preserved with 
Euro-Collins and Carolina rinse solutions for 24 hours but not reperfused with 
blood, had significantly more viable endothelial cells (groups I and 3 vs group 2, 
p < 0.0001; group 3 vs group 4, p < 0.02) and pneumocytes (group I vs groups 2 
and 4, group 3 versus group 2, p < 0.0001; group 3 vs group 4; p < 0.035) than 
groups 2 and 4, which were subsequently reperfused with blood. Groups 5 and 6, 
which received a second rinse, also had significantly more viable endothelial cells 
(p < 0.0005) and pneumocytes (p < 0.0001) than control groups, which were not 
rinsed before reperfusion. Conclusions: We conclude that damage to pulmonary 
allografts resulting from prolonged ischemia is ccentuated by repeffusion with 
blood. We also conclude that preservation with a single flush of Euro-Coliins or 
Carolina rinse solution does not offer adequate protection, whereas a second rinse 
before reperfusion significantly decreases the number of damaged cells within the 
allograft. (J Thorac Cardiovasc Surg 1996;112:1010-6) 
W hen subjected to prolonged cold ischemia, most solid organs show a cellular injury that primar- 
ily involves the vascular endothelium. The lung 
allograft is invaded with activated neutrophils, lyre- 
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phocytes, and macrophages capable of producing or 
promoting the release of cytokines and other vaso- 
active substances, which further accelerates endo- 
thelial cell damage. This injury is accentuated after 
reperfusion. Different types of preservative solu- 
tions and different methods of lung preservation 
have been used to try to the minimize damage after 
reperfusion of lung allografts. Results, however, 
have not been convincing, and none of these meth- 
ods has been widely accepted in clinical practice. 
The most widespread method of lung preservation is 
the use of a single pulmonary artery flush with cold, 
modified Euro-Collins solution (ECS), 1 an intracel- 
lular solution with bloodlike properties originally 
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designed for kidney preservation. In contrast to 
other organs such as the kidney, however, the lung 
cannot be kept ischemic for more than 12 hours, 
when ECS is used, without the risk of severe graft 
dysfunction. 
Recently, the use of a second flush with Carolina 
rinse solution (CRS) before reperfusion has been 
suggested as a means to improve outcome in liver 
transplantation recipients. 2 Currin, Thurman, and 
LeMasters 3 reported a decrease in the number of 
damaged cells in rat liver grafts perfused with a 
second rinse of CRS when compared with perfusion 
with University of Wisconsin solution alone. CRS is 
an extracellular solution with a cocktail of additives 
such as antioxidants, vasodilators, and different sub- 
strates such as glucose and fructose, which may 
theoretically prevent or counteract he effects of 
ischemia-reperfusion injury. 4 The concept of a sec- 
ond rinse is not new, being widely practiced after 
administration of crystalloid cardioplegic solution in 
cardiac operations. Among many other potential 
benefits, the second rinse has been shown to im- 
prove buffering and replenish important substrates 
such as glucose or adenosine triphosphate, which 
may have become depleted or degraded. 5 Thus it is 
likely that this simple method may be advanta- 
geously applicable in lung transplantation. The pur- 
pose of this study was to determine whether admin- 
istration of a second rinse of preservative solution 
before reperfusion could preserve the lungs better 
than if the lungs were treated with a single flush 
using the same solutions. In this preliminary study 
the solutions tested were modified ECS (an intra- 
cellular solution) and CRS (an extracellular solu- 
tion). The effects of this strategy on the integrity and 
viability of graft pneumocytes and endothelial cells 
from rat lungs preserved for 24 hours were exam- 
ined. 
Method 
Male Sprague-Dawley rats (250 to 300 gm) were anes- 
thetized by a mixed intraperitoneal injection of ketamine 
hydrochloride (100 mg/kg), xylazine hydrochloride (6 mg/ 
kg), and atropine (1 mg/kg) and were orotracheally intu- 
bated with a 16-gauge intravenous catheter. Animals were 
then connected to a pressure-controlled ventilator (Hock 
Loos infant ventilator, Hock Loos Medical Equipment, 
Amsterdam, The Netherlands) with intermittent positive- 
pressure ventilation (respiratory rate of 60 breaths/min, 
inspiratory pressure of 1.2 kPa, positive end-expiratory 
pressure of 0.3 kPa, and flow rate of 3.5 L/rain of 100% 
humidified, warmed oxygen). 
The rats were placed in the supine position and the 
abdomen was opened by a midline and transverse incision. 
The diaphragm was cut from its costal attachment to 
visualize the thoracic avity. The right ribs, muscles, and 
skin were cut near the spine and the anterior chest wall 
was displaced to the left side. At this time animals 
received an injection of 300 U of heparin into the inferior 
vena cava to prevent hrombosis. The right ventricle was 
punctured with an 18-gauge needle and the lungs were 
flushed with ice cold preservative solution at a rate of 3 to 
4 ml/min per gram for 2 minutes. The lungs were removed 
en bloc with the heart and stored at approximately 4 ° C for 
24 hours. 
All animals were given humane care in compliance with 
the Animal Care Committee regulations of the Montreal 
General Hospital and McGill University, as well as with 
the "Principles of Laboratory Animal Care" formulated 
by the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the National Academy of Sciences and pub- 
lished by the National Institutes of Health (NIH Publica- 
tion No. 85-23, revised 1985). 
Single versus double flush. Six groups (n = 6 each) 
were studied. Groups 1 to 4 served as controls and did not 
receive a second flush. 
Group L Lungs were preserved with ECS, stored for 24 
hours at approximately 4 ° C, and then stained with trypan 
blue stain for 5 minutes (ischemia only with no reperfu- 
sion). 
Group 2. Lungs were preserved with ECS for 24 hours, 
like group 1 lungs. Then the lungs were reperfused with 
warm rat blood at a rate of 3 to 4 ml/min per gram of 
tissue for 10 minutes. The lungs were then stained with 
trypan blue stain (ischemia plus reperfusion). 
Group 3. Lungs were preserved with the CRS, stored 
for 24 hours, and then stained with trypan blue stain for 5 
minutes (ischemia only with no reperfusion). 
Group 4. Lungs were preserved with CRS, stored for 24 
hours, and reperfused with blood. The lungs were then 
stained with trypan blue stain (ischemia plus reperfusion). 
In groups 5 and 6 the lungs received a second flush of 
either ECS or CRS at 4 ° C before reperfusion with blood. 
Group 5. Lungs were preserved with ECS, stored for 24 
hours at approximately 4 ° C, and then rinsed again with 
ECS at a rate of 3 to 4 ml/min per gram of tissue for 2 
minutes before reperfusion. The lungs were then reper- 
fused with blood and stained with trypan blue stain. 
Group 6. Lungs were preserved with ECS, stored for 24 
hours as in group 5, and then rinsed with CRS at a rate of 
3 to 4 ml/min per gram of tissue for 2 minutes before 
reperfusion. The lungs were then reperfused with blood 
and stained with trypan blue stain. 
Histologie assessment of cell viability. Lungs were 
stained to determine cell viability by the infusion of trypan 
blue stain, 500/xmol/L, through the right ventricle for 5 
minutes at a rate of 3 to 4 ml/min per gram. Lung blocks 
were then fixed with PoIy/LEM fixative, methanol free 
(Polysciences Inc., Warrington, Pa.). After fixation, the 
lung tissues were embedded in water-soluble glycol 
methacrylate, sectioned, and stained with eosin. Trypan 
blue-stained nuclei of nonviable endothelial cells and 
pneumocytes were counted in ten fields of power by an 
individual blinded to the method of preservation. The 
total number of dead cells was added and recorded. 
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Fig. 1. Endothelial cell viability in rat lungs after 24 hours of cold ischemia. #p < 0.0001 versus ECS or 
CRS + reperfusion, p = 0.008 versus CRS with no reperfusion, and p = 0.0011 versus ECS with no 
reperfusion; *p = 0.0005 versus CRS + reperfusion, p < 0.0001 versus ECS + reperfusion, andp = 0.0335 
versus ECS with no reperfusion; xp = 0.0199 versus CRS with no reperfusion; ~'p < 0.0001 versus ECS or 
CRS with no reperfusion and CRS + reperfusion. 
Statistics. Statistical analysis was determined by means 
of a one-factor analysis of variance. A p value of 0.05 or 
less was considered statistically significant. All data are 
expressed as mean +_ standard error of the mean. 
Results 
Assessment of endothelial cell and pneumocyte 
viability by use of trypan blue staining. Control 
lungs preserved with ECS or CRS and subjected to 
24 hours of ischemia alone (groups 1 and 3) had 
significantly fewer dead endothelial cells than lungs 
from their corresponding control groups (groups 2 
and 4), which were reperfused with blood (group 1 
vs group 2, p < 0.0001; group 3 vs group 2, p < 
0.0001; group 3 vs group 4: p < 0.02). 
Both groups receiving a second flush with ECS or 
CRS before reperfusion (groups 5 and 6) had sig- 
nificantly fewer dead endothelial cells than control 
groups 1, 2, and 4 (groups 5 and 6 vs groups 2 and 4, 
p < 0.0005; group 5 vs group 1, p < 0.035; group 6 
vs group 1, p < 0.001). However, no difference was 
detected between groups 5 and 6 with regard to 
endothelial cell viability. In lungs rinsed with CRS 
before reperfusion (group 6), the likelihood of 
endothelial cell death was significantly lower than in 
those lungs that had ischemic injury without reper- 
fusion and that were preserved with CRS (group 3) 
(group 6 vs group 3, p < 0.008). This was not the 
case when lungs were rinsed with ECS (group 5 vs 
group 3, p -- not significant; see Fig. 1). 
Pneumocyte cell death was significantly less prev- 
alent when ECS was used as the preservative with- 
out reperfusion (group 1) than in all other control 
groups (group 1 vs groups 2, 3, and 4, p < 0.0001). 
Pneumocyte cell death was also significantly less 
prevalent when CRS was used as the preservative 
(group 3) than in control groups that were reper- 
fused with blood (group 3 vs groups 2 and 4, p < 
0.0001). Although cell death was more prevalent 
when CRS was used as the preservative than when 
ECS was used (group 1 vs group 3, p < 0.035), on 
reperfusion the CRS group (group 4) had signifi- 
cantly more viable pneumocytes than the ECS group 
(group 2) (group 4 vs group 2, p < 0.0001). 
Both groups treated with a second flush (groups 5 
and 6) had significantly fewer dead pneumocytes 
than did the control groups that were not rinsed 
(groups 1 to 4), irrespective of the preservation 
solution used (groups 5 and 6 vs groups 1 to 4, p < 
0.002). However, there were significantly more dead 
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Fig. 2. Pneumocyte viability in rat lungs after 24 hours of cold ischemia. *p < 0.0001 versus control groups 
andp = 0.0056 versus ECS + ECS rinse + reperfusion; #p < 0.0001 versus CRS with no reperfusion and 
ECS or CRS + reperfusion andp = 0.0017 versus ECS with no reperfusion; ?p < 0.0001 versus ECS + 
reperfusion andp = 0.0348 versus CRS + reperfusion; xp < 0.0001 versus ECS + reperfusion; 
~+p < 0.0001 versus control groups. 
pneumocytes when ECS was used as the rinse 
(group 5) than when CRS was used (group 6) (group 
5 vs group 6, p < 0.006; see Fig. 2). 
Discussion 
During lung transplantation, donor lungs are sub- 
jected to an obligatory period of cold and warm 
ischemia t the time of organ retrieval and implanta- 
tion. However, it is during the period of reperfusion 
that most of the organ damage seems to occur through 
the release of oxygen-derived free radicals and other 
metabolites. 6-s It is for this reason that the major 
concern early after transplantation has focused on the 
immediate injm-y to the lung in what is described as the 
"reimplantation response." The present study sup- 
ports this hypothesis, inasmuch as reperfusion resulted 
in significantly more killing of endothelial cells and 
pneumocytes than did cold ischemia lone. 
During reperfusion injury a complex cascade of 
various pathogenic mechanisms can cause immedi- 
ate lung damage. These mechanisms include forma- 
tion of oxygen-derived free radicals, 7'8 calcium in- 
flux into the cells, 9 and leukocyte, platelet, 1° and 
complement activation. 11 Likewise, lung function 
can be improved after transplantation when free 
radical scavengers such as dimethylthiourea, 8 super- 
oxide dismutase, and catalase, 7 are administered 
before reperfusion. Calcium channel blockers and 
vasodilators have also been shown to prevent isch- 
emia-reperfusion injury. I2 
CRS (developed at the University of North Caro- 
lina) was developed to counteract factors that may 
cause organ damage after reperfusion. It is an 
extracellular solution that contains electrolytes sim- 
ilar to plasma (NaC1, 115 retool/L; KC1, 5 mmol/L; 
CaC12, 1.3 mmol/L; KH2PO4, 1 mmol/L; and 
MgSO4, 1.2 retool/L). 1 Other constituents include 
antioxidants uch as allopurinol, desferrioxamine, 
and glutathione; vasodilators uch as nicardipine 
and adenosine; hydroxylethyl starch to protect 
against edema; and fructose, glucose, and insulin to 
help regenerate adenosine triphosphate stores) 
In this study, we have shown that a second 
pulmonary artery flush before reperfusion, regard- 
less of the type of rinse solution used, is beneficial to 
the lung graft by preventing lethal injury to endo- 
thelial cells and pneumocytes. This may be attrib- 
uted to the flushing out of metabolites uch as 
1 0 1 4 Serrick et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1996 
oxygen-derived free radicals, activated cells, and 
components of complement that can damage the 
lung parenchyma. Although a second flush with 
either ECS or CRS did protect the lung, CRS 
provided greater protection than did ECS. Pneumo- 
cyte and endothelial cell death was significantly less 
prevalent in lungs preserved with CRS. This differ- 
ence can be attributed to the properties of the 
solution itself. Direct observation of the hepatic 
microcirculation by means of in vivo microscopy has 
shown that CRS had a beneficial effect on microcir- 
culatory manifestations of ischemia-reperfusion n- 
jury in rat liver grafts. Both microcirculatory perfu- 
sion failure and white blood cell accumulation and 
adherence were reduced after grafts were rinsed 
with CRS. 13 A substantial decrease in vascular e- 
sistance is apparent after perfusion with CRS. The 
main cause for this decreased resistance is believed 
to be protection of the endothelial cells of the 
microvasculature. Thus Sato and colleagues TM have 
demonstrated that sinusoidal endothelial cells of the 
liver were better protected by CRS than by other 
solutions used as a rinse after 24 hours of storage 
with University of Wisconsin solution. Also, several 
components of CRS have been shown previously to 
protect against lethal injury to cells depleted of 
adenosine triphosphate, including fructose, 15 acidic 
pH, ~6 the antioxidants desferrioxamine and allopuri- 
no1,17,18 and dihydropyridine-type calcium channel 
blockers. 3 
On the other hand, ECS is an intracellular solu- 
tion with a low sodium, high potassium concentra- 
tion and has little protective ffect against reperfu- 
sion injury other than providing cells with a 
homeostatic environment during the storage or isch- 
emic stage. It causes pulmonary vasoconstriction 19 
in lung allografts and has been shown by many 
authors to produce poorer airway pressures, lung 
compliance, and pulmonary vascular esistance after 
long ischemic periods than do other lung storage 
solutions. 2°-25 
The type of preservation solution to be used 
during lung procurement has been the subject of 
much debate. In fact, controversy still exists as to 
whether an intracellular or extracellular solution is 
better. Experimentally and to a certain extent clini- 
cally, both intracellular and extracellular products 
have yielded favorable results. The current method 
used by most centers practicing clinical lung trans- 
plantation is the standard pulmonary artery flush 
with modified ECS, 2 an intracellular solution mod- 
ified with bicarbonate and magnesium. However, 
other intracellular solutions uch as the University 
of Wisconsin solution have been shown experimen- 
tally in dogs to be superior to ECS as a preservative 
for lung transplantation, 26' 27 with extended preser- 
vations times of up to 24 hours. On the other hand, 
extracellular solutions such as low-potassium dex- 
tran have provided significantly better lung preser- 
vation than did ECS after 12 and 18 hours of 
ischemiaY In the present study, endothelial cell 
death after reperfusion with blood was significantly 
more prevalent in lungs flushed with modified ECS 
after 24 hours of ischemia than in lungs that were 
ischemic but not reperfused. However, rinsing the 
graft with an extracellular solution before reperfu- 
sion resulted in significantly less killing of endothe- 
lial cells. The CRS (extracellular) protected pneu- 
mocytes better before the reperfusion stage than did 
ECS (intraceUular) as determined by the presence 
of significantly more viable pneumocytes after 
reperfusion with CRS. 
This observation supports a potentially beneficial 
role of extracellular ather than an intracellular 
solutions in lung transplantation. The rationale for 
using a high-potassium solution was thought o be 
the abolishment of the transmembrane potassium 
ion gradient, which might decrease cell swelling 
directly and would limit potassium ion leakage from 
preserved cells. 28 However, intracellular solutions 
have been considered to induce pulmonary vasocon- 
striction during flushing, causing heterogeneous di - 
tribution of the preservative solution and incom- 
plete protection through cooling. 29 This may also 
result in an increase in passenger donor blood cells 
in the pulmonary vasculature. A high potassium 
concentration may also acutely raise pulmonary 
artery flush pressures, which may disrupt endothe- 
lial cell integrity and contribute to pulmonary 
edema both during pulmonary artery flushing and 
during postischemic reperfusion. 3°In fact, endothe- 
lial cells were better preserved with CRS than with 
ECS, regardless of whether CRS was used as a 
preservative or rinse solution. This distinction did 
not obtain for pneumocytes, inasmuch as ECS used 
as a preservative and rinse solution also helped to 
prevent pneumocyte death. However, significantly 
more pneumocytes died after reperfusion when ECS 
was used as both a preservative and a second flush 
than when CRS was used as the second rinse. The 
ECS rinse decreased pneumocyte death, but not to 
the same extent noted when CRS was used before 
reperfusion. This observation agrees with evidence 
from rat pneumocyte cell culture models, which 
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suggest hat incubation in high-potassium intracel- 
lular solutions may be more  injurious than a variety 
of low-potassium preservat ion solutions under  cell 
culture condit ions. 31' 32 
Despi te  the suggested benefits of using drugs that 
act l ike oxygen-derived free radical  scavengers or 
vasodi lators, the most common preservat ion solu- 
tion currently used is ECS. In this pi lot study using 
a simple in vitro model  of ischemia-reperfusion 
injury, we have shown the superior i ty of an extra- 
cel lular solution as a preservat ive and also have 
demonstrated a benefit  of  using a second rinse by 
reducing the number  of in jured endothel ia l  cells and 
pneumocytes after 24 hours of  ischemia. It is possi- 
ble that the CRS minimizes reperfusion injury by 
maintain ing cell membrane integrity. Fur ther  stud- 
ies are required to evaluate the effect of a second 
rinse on pu lmonary  graft function in vivo. We are 
currently using a canine left lung al lotransplantat ion 
model  observed for 6 hours of  reperfus ion to assess 
the adequacy of a second rinse solut ion with empha-  
sis on functional outcome. 
Many thanks to Dr. John Lamasters from the University 
of North Carolina for the generous upply of CRS. 
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